MyHeritage Releases Groundbreaking Feature to Animate the Faces in Still Photos
25.2.2021 17:54:00 EET | Business Wire | Press release
MyHeritage, the leading global service for discovering your past and empowering your future, announced today the release of Deep Nostalgia™, a new feature that animates the faces in still photos. Deep Nostalgia™ gives family history a fresh new perspective by producing a realistic depiction of how a person could have moved and looked if they were captured on video. MyHeritage is the only company to offer a complete suite of features for colorizing, restoring, enhancing, and now animating historical photos.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210225005747/en/
Introducing Deep Nostalgia™ (Photo: Business Wire)
The technology for animating the faces in photos was licensed by MyHeritage from D-ID, a company that specializes in video reenactment using deep learning. Deep Nostalgia™ uses several pre-recorded driver videos prepared by MyHeritage, which direct the movements in the animation and consist of sequences of real human gestures. A preferred driver is automatically selected for each face based on its orientation, and then seamlessly applied to the photo. The result is a short, high-quality video animation of an individual face that can smile, blink, and move. To achieve optimal results, the photos are enhanced prior to animation using the MyHeritage Photo Enhancer, which brings blurry and low-resolution faces into focus and increases their resolution.
Deep Nostalgia™ is the newest AI-based photo tool on MyHeritage, and comes on the heels of two highly-acclaimed features that the company released last year, the MyHeritage Photo Enhancer and MyHeritage In Color™, which colorizes black and white photos and was recently expanded to also restore the colors in faded color photos. These features have gone viral and have been used over 30 million times. MyHeritage keeps building on that momentum by adding new, cutting-edge tools for historical photos that inspire a fresh appreciation for family history and nostalgic family photos.
“You’ll have a ‘wow moment’ when you see a treasured family photo come to life with Deep Nostalgia™,” said Gilad Japhet, Founder and CEO of MyHeritage. “Seeing our beloved ancestors’ faces come to life in a video simulation lets us imagine how they might have been in reality, and provides a profound new way of connecting to our family history.”
“This new product integration is an exciting collaboration between two innovative companies,” said Gil Perry, Co-Founder and CEO of D-ID. “We’re thrilled that our technology will be accessible to millions of people on MyHeritage and hope many of them will enjoy the impact of video reenactment for historical photos.”
Integration into the MyHeritage platform
Deep Nostalgia™ is a freemium feature on MyHeritage. Users can animate several photos for free, regardless of the number of faces in the photo. Beyond that, continued use requires a subscription. The video animation can easily be shared with family and friends on Facebook, Twitter, WhatsApp, and other social media.
About MyHeritage
MyHeritage is the leading global discovery platform for exploring family history. With billions of historical records and family tree profiles, and with sophisticated matching technologies that work across all its assets, MyHeritage allows users to discover their past and empower their future. MyHeritage DNA is one of the world’s largest consumer DNA databases, with more than 4.7 million customers. MyHeritage is the most popular DNA test and family history service in Europe. Since 2020, MyHeritage is home to the world’s best AI technologies for enhancing and colorizing historical photos. www.myheritage.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210225005747/en/
Contact information
MyHeritage
Rafi Mendelsohn
Director of PR & Social Media
Phone: 917-725-5018
Email: pr@myheritage.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom